Eli Lilly's Biggest Problem in 2013


Eli Lilly currently has several blockbuster drugs on the market -- but lookout investors, there are patent expirations aplenty for this pharma giant ahead. Much like Merck , which is dealing with the recent loss of exclusivity for its top-selling drug Singulair, Lilly has to rely on its pipeline to quickly produce drugs with massive market opportunities. In this video, health-care analyst Max Macaluso dives into the company's most worrying patent expiration of 2013.

Can Eli Lilly Defeat the Patent CliffOver the next two years, Eli Lilly will see nearly $0.40 of every $1.00 in sales exposed to generic competition. How does the company plan to respond to this huge patent cliff? Better yet, what does this mean for investors? In a brand new premium report on Eli Lilly, The Motley Fool's top pharmaceuticals analyst delves into everything investors need to know about the stock today. Simply click here now to claim your copy.

The article Eli Lilly's Biggest Problem in 2013 originally appeared on Fool.com.

Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.